Regulation of platelet membrane protein shedding in health and disease

Platelets

Volumn 28, Issue 4, 2017, Pages 342-353

  Au, Amanda E ^a,b   Josefsson, Emma C ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD40L; GPIb ; GPVI; P selectin; Platelets; Shedding

Indexed keywords

CD40 LIGAND; GLYCOPROTEIN; PADGEM PROTEIN; MEMBRANE PROTEIN;

APOPTOSIS; BLOOD BANK; CEREBROVASCULAR DISEASE; DOWN REGULATION; EX VIVO STUDY; HEALTH; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REGULATORY MECHANISM; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE MEMBRANE; THROMBOCYTE PRESERVATION; THROMBOEMBOLISM; ANIMAL; BLOOD; DISEASES; METABOLISM; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; DISEASE; HUMANS; MEMBRANE PROTEINS; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION;

EID: 85020877270     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2016.1203401     Document Type: Review

References (169)

1. Bryckaert M, Rosa JP, Denis CV, Lenting PJ., Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015 Jan;72(2):307–26. doi:10.1007/s00018-014-1743-8.
2. Flaumenhaft R., Platelet secretion. In:AD, Michelson, editor. Platelets. San Diego:Academic Press; 2013. p. 343–365.
3. Gardiner EE, Andrews RK., Platelet receptor expression and shedding:glycoprotein Ib-IX-V and glycoprotein VI. Transfusion Med Rev 2014;28:56–60.
4. Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, Speicher DW, Grosser T, et al. Deciphering the human platelet sheddome. Blood 2011;117:e15–e26.
5. Zhang W, Deng W, Zhou L, Xu Y, Yang W, Liang X, Wang Y, Kulman JD, Zhang XF, Li R., Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood 2015;125:562–569.
6. Andrews RK, Berndt MC., The GPIb-IX-V complex. In:AD, Michelson, editor. Platelets. San Diego:Academic Press; 2013. p. 195–213.
7. Pollitt AY, Hughes CE, Watson SP., GPVI and Clec-2. In:AD, Michelson, editor. Platelets. San Diego:Academic Press; 2013. p. 215–231.
8. Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD., Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004;95:677–683.
9. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC., Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. JTH 2007;5:1530–1537.
10. Bergmeier W, Rabie T, Strehl A, Piffath CL, Prostredna M, Wagner DD, Nieswandt B., GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost 2004;91:951–958.
11. Bender M, Hofmann S, Stegner D, Chalaris A, Bosl M, Braun A, Scheller J, Rose-John S, Nieswandt B., Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 2010;116:3347–3355.
12. Facey A, Pinar I, Arthur JF, Qiao J, Jing J, Mado B, Carberry J, Andrews, RK, Gardiner EE., A-disintegrin-and-metalloproteinase (ADAM) 10 activity on resting and activated platelets. Biochemistry 2016;55:1187–1194.
13. Rabie T, Strehl A, Ludwig A, Nieswandt B., Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 2005;280:14462–14468.
14. Bergmeier W, Burger PC, Piffath CL, Hoffmeister KM, Hartwig JH, Nieswandt B, Wagner DD., Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003;102:4229–4235.
15. Al-Tamimi M, Tan CW, Qiao J, Pennings GJ, Javadzadegan A, Yong AS, Arthur JF, Davis AK, Jing J, Mu FT, et al. Pathologic shear triggers shedding of vascular receptors:a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012;119:4311–4320.
16. Cheng H, Yan R, Li S, Yuan Y, Liu J, Ruan C, Dai K., Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ibalpha shedding. American journal of physiology. Heart Circ Physiol 2009;297:H2128–H2135.
17. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, Josefsson EC, Alwis I, Ono A, Willcox A, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663–1674.
18. Brill A, Chauhan AK, Canault M, Walsh MT, Bergmeier W, Wagner DD., Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res 2009;84:137–144.
19. Canault M, Duerschmied D, Brill A, Stefanini L, Schatzberg D, Cifuni SM, Bergmeier W, Wagner DD., p38 mitogen-activated protein kinase activation during platelet storage:consequences for platelet recovery and hemostatic function in vivo. Blood 2010;115:1835–1842.
20. Jansen AJ, Josefsson EC, Rumjantseva V, Liu QP, Falet H, Bergmeier W, Cifuni SM, Sackstein R, von Andrian UH, Wagner DD, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice. Blood 2012;119:1263–1273.
21. Aktas B, Pozgajova M, Bergmeier W, Sunnarborg S, Offermanns S, Lee D, Wagner DD, Nieswandt B., Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biolog Chem 2005;280:39716–39722.
22. Al-Tamimi M, Mu FT, Arthur JF, Shen Y, Moroi M, Berndt MC, Andrews RK, Gardiner EE., Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding. Platelets 2009;20:75–82.
23. Wijeyewickrema LC, Gardiner EE, Moroi M, Berndt MC, Andrews RK., Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI. Thromb Haemost 2007;98:1285–90.
24. Andrews RK, Gardiner EE, Asazuma N, Berlanga O, Tulasne D, Nieswandt B, Smith AI, Berndt MC, Watson SP., A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI. J Biol Chem 2001;276:28092–28097.
25. Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, Berndt MC, Gardiner EE, Andrews RK., Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011;117:3912–3920.
26. Duerschmied D, Canault M, Lievens D, Brill A, Cifuni SM, Bader M, Wagner DD., Serotonin stimulates platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17). JTH 2009;7:1163–1171.
27. Berndt MC, Karunakaran D, Gardiner EE, Andrews RK., Programmed autologous cleavage of platelet receptors. JTH 2007;5(Suppl 1):212–219.
28. Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR., A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci USA 2001;98:1823–1828.
29. Hsu CC, Wu WB, Huang TF., A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions. JTH 2008;6:1578–1585.
30. Hsu CC, Wu WB, Chang YH, Kuo H, Huang TF., Antithrombotic effect of a protein-type I class snake venom metalloproteinase, kistomin, is mediated by affecting glycoprotein Ib-von Willebrand factor interaction. Mol Pharmacol 2007;72:984–92.
31. Ward CM, Andrews RK, Smith AI, Berndt MC., Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry 1996;35:4929–4938.
32. Wijeyewickrema LC, Gardiner EE, Shen Y, Berndt MC, Andrews RK., Fractionation of snake venom metalloproteinases by metal ion affinity:a purified cobra metalloproteinase, Nk, from Naja kaouthia binds Ni2+-agarose. Toxicon Off J Int Soc Toxinol 2007;50:1064–1072.
33. Bergmeier W, Bouvard D, Eble JA, Mokhtari-Nejad R, Schulte V, Zirngibl H, Brakebusch C, Fassler R, Nieswandt B., Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha. J Biol Chem 2001;276:25121–25126.
34. Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, Gamble JR, Vadas MA, Berndt MC., Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992;175:1147–1150.
35. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, Handa M., Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem 1994;269:23708–23715.
36. Johnston GI, Bliss GA, Newman PJ, McEver RP., Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J Biol Chem 1990;265:21381–21385.
37. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD., P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000;191:1413–1422.
38. Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD., P-selectin promotes neutrophil extracellular trap formation in mice. Blood 2015;12:242–246.
39. Furie B, Furie BC, Flaumenhaft R., A journey with platelet P-selectin:the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001;86:214–221.
40. Vandendries ER, Furie BC, Furie B., Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004;92:459–466.
41. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, et al. An essential role for ectodomain shedding in mammalian development. Science (New York, NY) 1998;282:1281–1284.
42. Dole VS, Bergmeier W, Patten IS, Hirahashi J, Mayadas TN, Wagner DD. PSGL-1, regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost 2007;98:806–812.
43. van Kooten C, Banchereau J., CD40-CD40 ligand. J Leukocyte Biol 2000;67:2–17.
44. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA., The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047–1054.
45. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.
46. Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, Duriez M, Brandes RP, Lutgens E, Tedgui A, Boulanger CM., CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008;52:1302–1311.
47. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J., Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 2003;278:32801–32809.
48. Matthies KM, Newman JL, Hodzic A, Wingett DG., Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006;241:47–58.
49. Yacoub D, Benslimane N, Al-Zoobi L, Hassan G, Nadiri A, Mourad W., CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner. J Biol Chem 2013;288:36083–36093.
50. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD., CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nat Med 2002;8:247–252.
51. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR., Platelet-derived CD40L:the switch-hitting player of cardiovascular disease. Circulation 2002;106:896–899.
52. Wenzel F, Rox J, Reinboldt S, Weber AA, Giers G, Fischer J., Release of soluble CD40L by matrix metalloprotease-2 (MMP-2)-dependent shedding of platelets and its subsequent accumulation in stem cell products of autologous donors. J Stem cells Regener Med 2010;6:66–67.
53. Rahman M, Zhang S, Chew M, Syk I, Jeppsson B, Thorlacius H., Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis. JTH 2013;11:1385–1398.
54. Aloui C, Prigent A, Sut C, Tariket S, Hamzeh-Cognasse H, Pozzetto B, Richard Y, Cognasse F, Laradi S, Garraud O., The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci 2014;15:22342–22364.
55. Fullard JF., The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004;10:1567–1576.
56. El Fakhry Y, Alturaihi H, Yacoub D, Liu L, Guo W, Leveille C, Jung D, Khzam LB, Merhi, Y, Wilkins JA, Li H, Mourad W., Functional interaction of CD154 protein with alpha5beta1 integrin is totally independent from its binding to alphaIIbbeta3 integrin and CD40 molecules. J Biol Chem 2012;287:18055–18066.
57. Hassan GS, Merhi Y, Mourad WM., CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009;30:165–172.
58. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–72.
59. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW., CD40 and epithelial cells:across the great divide. Immunol Today 1998;19:502–506.
60. Czabotar PE, Lessene G, Strasser A, Adams JM., Control of apoptosis by the BCL-2 protein family:implications for physiology and therapy. Nature reviews. Mol cell Biol 2014;15:49–63.
61. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT., Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173–1186.
62. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943–951.
63. Kile BT., The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014;165:217–226.
64. Lebois M, Josefsson EC., Regulation of platelet lifespan by apoptosis. Platelets 2016; [epub ahead of print] doi:10.3109/09537104.2016.1161739
65. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. The J Exp Med 2011;208:2017–2031.
66. Kodama T, Takehara T, Hikita H, Shimizu S, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Tadokoro S, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010;138:2487-98,2498.e1–e7.
67. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency:molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011;286:13905–13913.
68. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition:results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:488–496.
69. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, O’Reilly LA, Henley KJ, Ono A, Hsiao S, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009;114:663–666.
70. Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM., BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011;117:7145–154.
71. Murphy S, Gardner FH., Effect of storage temperature on maintenance of platelet viability–deleterious effect of refrigerated storage. N Engl J Med 1969;280:1094–1098.
72. Ohto H, Nollet KE., Overview on platelet preservation:better controls over storage lesion. Transfusion Apheresis Sci Off J World Apheresis Assoc Off J Eur Soc Haemapheresis 2011;44:321–325.
73. Albanyan AM, Harrison P, Murphy MF., Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009;49:108–117.
74. Cookson P, Sutherland J, Turner C, Bashir S, Wiltshire M, Hancock V, Smith K, Cardigan R., Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfusion Med (Oxf Engl) 2010;20:392–402.
75. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ., The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40:1320–1329.
76. Soslau G, Giles, J., The loss of sialic acid and its prevention in stored human platelets. Thromb Res 1982;26:443–455.
77. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ., Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003;43:857–866.
78. Liang X, Russell SR, Estelle S, Jones LH, Cho S, Kahn ML, Berndt MC, Bunting ST, Ware J, Li R., Specific inhibition of ectodomain shedding of glycoprotein Ibalpha by targeting its juxtamembrane shedding cleavage site. JTH 2013;11:2155–2162.
79. Grozovsky R, Giannini S, Falet H, Hoffmeister KM., Regulating billions of blood platelets:glycans and beyond. Blood 2015;126:1877–1884.
80. Hoffmeister KM., The role of lectins and glycans in platelet clearance. JTH 2011;9(Suppl 1):35–43.
81. Gasic GJ, Gasic TB, Stewart CC., Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968;61:46–52.
82. Kotze HF, van Wyk V, Badenhorst PN, Heyns AD, Roodt JP, Lotter MG., Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thromb Haemost 1993;70:676–680.
83. Stenberg PE, Levin J, Baker G, Mok Y, Corash L., Neuraminidase-induced thrombocytopenia in mice:effects on thrombopoiesis. J Cell Physiol 1991;147:7–16.
84. Greenberg JP, Packham MA, Guccione MA, Rand ML, Reimers HJ, Mustard JF., Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979;53:916–927.
85. Rumjantseva V, Grewal PK, Wandall HH, Josefsson EC, Sorensen AL, Larson G, Marth, JD, Hartwig JH, Hoffmeister KM., Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009;15:1273–1280.
86. Sorensen AL, Rumjantseva V, Nayeb-Hashemi S, Clausen H, Hartwig JH, Wandall HH, Hoffmeister KM., Role of sialic acid for platelet life span:exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009;114:1645–1654.
87. Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM., The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015;21:47–54.
88. Hoffmeister KM, Felbinger TW, Falet H, Denis CV, Bergmeier W, Mayadas TN, von Andrian UH, Wagner DD, Stossel TP, Hartwig JH., The clearance mechanism of chilled blood platelets. Cell 2003;112:87–97.
89. Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP., Glycosylation restores survival of chilled blood platelets. Science (New York, NY) 2003;301:1531–1534.
90. Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM., The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem 2005;280:18025–18032.
91. Gitz E, Koekman CA, van den Heuvel DJ, Deckmyn H, Akkerman JW, Gerritsen HC, Urbanus RT., Improved platelet survival after cold storage by prevention of glycoprotein Ibalpha clustering in lipid rafts. Haematologica 2012;97:1873–1881.
92. van der Wal DE, Du VX, Lo KS, Rasmussen JT, Verhoef S, Akkerman JW., Platelet apoptosis by cold-induced glycoprotein Ibalpha clustering. JTH 2010;8:2554–2562.
93. Au AE, Sashindranath M, Borg RJ, Kleifeld O, Andrews RK, Gardiner EE, Medcalf RL, Samson AL., Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase. Cell Death Dis 2014;5:e1410.
94. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK., Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20:143–149.
95. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY., Increased soluble P-selectin in patients with haematological and breast cancer:a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagulation Fibrinol Int J Haemost Thromb 2001;12:43–50.
96. Williams SB, Sano M, Smith N, Horne M, Yarchoan R, Wyvill K, Zeichner S, Taylor P, Knudson T, Gralnick HR., Glycocalicin levels in the plasma of HIV+ patients:an indicator of platelet turnover. J Lab Clin Med 1998;132:303–307.
97. Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE., The platelet Fc receptor, FcgammaRIIa. Immunol Rev 2015;268:241–252.
98. Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI., Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. JTH 2008;6:1175–1182.
99. Blann AD, Nadar SK, Lip GY., The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24:2166–2179.
100. Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK., The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:1081–1085.
101. Jilma B, Eichler HG, Vondrovec B, Breiteneder H, Kyrle PA, Kitzweger E, Kapiotis S, Speiser W., Effects of desmopressin on circulating P-selectin. Br J Haematol 1996;93:432–436.
102. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN., Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994;83:1535–1541.
103. McEver RP., Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746–756.
104. Berger G, Hartwell DW, Wagner DD., P-Selectin and platelet clearance. Blood 1998;92:4446–4452.
105. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J Valeri CR. In vivo tracking of platelets:circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci US A 1996;93:11877–11882.
106. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G., Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998;97:953–957.
107. Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, Watanabe K, Ikeda Y., Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993;84:702–710.
108. Blann AD, Noteboom WM, Rosendaal FR., Increased soluble P-selectin levels following deep venous thrombosis:cause or effect? Br J Haematol 2000;108:191–193.
109. Gremmel T, Ay C, Seidinger D, Pabinger I, Panzer S, Koppensteiner R., Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. J Vasc Surgery 2011;54:48s–55s.
110. Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M., Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008;156:193–200.
111. Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M., Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27:2165–2169.
112. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, Investigators CS., Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104–1111.
113. Lee Y, Lee WH, Lee SC, Ahn KJ, Choi YH, Park SW, Seo JD, Park JE., CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999;92:11–16.
114. Stellos K, Bigalke B, Stakos D, Henkelmann N, Gawaz M., Platelet-bound P-selectin expression in patients with coronary artery disease:impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. JTH 2010;8:205–207.
115. Bigalke B, Stellos K, Geisler T, Lindemann S, May AE, Gawaz M., Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol Off J German Cardiac Soc 2010;99:227–233.
116. Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Potz O, Joos T, May AE, Lindemann S, Gawaz M., Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009;104:352–357.
117. Pennings GJ, Yong AS, Wong C, Al-Tamimi M, Gardiner EE, Andrews RK, Kritharides L., Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma. Platelets 2014;25:639–642.
118. Ikeda H, Nakayama H, Oda T, Kuwano K, Muraishi A, Sugi K, Koga Y, Toshima H., Soluble form of P-selectin in patients with acute myocardial infarction. Coronary Artery Dis 1994;5:515–518.
119. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM., Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266–2268.
120. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L., Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614–620.
121. Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M., Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer’s disease. J Psychiatric Res 2008;42:746–751.
122. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, Hacke W., Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998;80:298–301.
123. Cherian P, Hankey GJ, Eikelboom JW, Thom J, Baker RI, McQuillan A, Staton J, Yi Q., Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke J Cereb Circ 2003;34:2132–2137.
124. Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May AE, Lindemann S, Melms A, Luft A, Gawaz M., Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 17:111–117.
125. Wurster T, Poetz O, Stellos K, Kremmer E, Melms A, Schuster A, Nagel E, Joos T, Gawaz M, Bigalke B., Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke. Platelets 24:2013;560–565.
126. Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK., Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke J Cereb Circu 2011;42:498–500.
127. Li J, Wang Y, Lin J, Wang D, Wang A, Zhao X, Liu L, Wang C, Wang Y, Investigators C., Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic Attack. Stroke J Cereb Circ 2015;46:1990–1992.
128. Ling JY, Shen L, Liu Q, Xue S, Ma W, Wu H, Li ZX, Zhu R., Changes in platelet GPIbalpha and ADAM17 during the acute stage of atherosclerotic ischemic stroke among Chinese. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen Ban 2013;33:438–442.
129. de Lemos JA, Zirlik A, Schonbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis:results from the Dallas Heart Study. Arteriosclerosis Thromb Vasc Biol 2005;25:2192–2196.
130. Blann AD, Dobrotova M, Kubisz P, McCollum CN., von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626–630.
131. Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, Baker RI, Hogarth PM, Kahn ML, Andrews RK, Berndt MC., Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors:de-ITAM-izing FcgammaRIIa. Blood 2008;111:165–174.
132. Steffan A, Pradella P, Cordiano I, Girolami A, De Marco L, Fabris F., Glycocalicin in the diagnosis and management of immune thrombocytopenia. Eur J Haematol 1998;61:77–83.
133. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, Bussel JB., Platelet production and platelet destruction:assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011;117:5723–5732.
134. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD., In vivo effects of eltrombopag on platelet function in immune thrombocytopenia:no evidence of platelet activation. Blood 2012;119:4066–4072.
135. Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI., Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol 2010;149:625–628.
136. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C., Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435–1441.
137. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK., Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999;42:871–881.
138. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ., The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947–955.
139. Nurden P, Tandon N, Takizawa H, Couzi L, Morel D, Fiore M, Pillois X, Loyau S, Jandrot-Perrus M, Nurden AT., An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. JTH 2009;7:1541–1549.
140. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps T. J, Hashimoto H., Soluble CD154 in rheumatoid arthritis:elevated plasma levels in cases with vasculitis. J Rheumatol 2001;28:2583–2590.
141. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV., Biologically active CD40 ligand is elevated in sickle cell anemia:potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26:1626–1631.
142. Holzer G, Pfandlsteiner T, Blahovec H, Trieb K, Kotz R., Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours. Wiener Medizinische Wochenschrift (1946) 2003;153:40–42.
143. Solooki S, Khozaei A, Shamsdin SA, Emami MJ, Khademolhosseini F., sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma. IJI 2013;10:229–237.
144. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD., Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92:185–190.
145. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J., Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012;120:3030–3038.
146. Qiao J, Schoenwaelder SM, Mason KD, Tran H, Davis AK, Kaplan ZS, Jackson SP, Kile BT, Andrews RK, Roberts AW, Gardiner EE., Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). Blood 2013;121:1479–1481.
147. Dymicka-Piekarska V, Kemona H., Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thromb Res 2009;124:80–83.
148. Ferroni P, Roselli M, Martini F, D’Alessandro R, Mariotti S, Basili S, Spila A, Aloe S, Palmirotta R, Maggini A, et al. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer. J Int du Cancer 2004;111:404–408.
149. Mantur M, Koper O, Snarska J, Sidorska A, Kruszewska-Wnorowska K., Evaluation of PDGF-AB and sP-selectin concentrations in relation to platelet count in patients with colorectal cancer before and after surgical treatment. Polskie Archiwum Medycyny Wewnetrznej 2008;118:345–350.
150. Dymicka-Piekarska V, Matowicka-Karna J, Osada J, Kemona H, Butkiewicz AM., Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma. Adv Med Sci 2006;51:304–308.
151. Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B., Platelet activation in patients with advanced gastric cancer. Neoplasma 2010;57:145–150.
152. Roselli, M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, et al. Soluble CD40 ligand plasma levels in lung cancer. Clinical cancer research:an official journal of the American Assoc Cancer Res 2004;10:610–614.
153. Roselli M, Mineo TC, Martini F, Mariotti S, Ambrogi V, Spila A, D’Alessandro R, Basili S, Guadagni F, Ferroni P., Soluble selectin levels in patients with lung cancer. Int J Biol Markers 2002;17:56–62.
154. Gong L, Cai Y, Zhou X, Yang H., Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. POR 2012;18:989–996.
155. Schadendorf D, Diehl S, Zuberbier T, Schadendorf C, Henz BM., Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 1996;192:89–93.
156. Caggiari L, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, Martorelli D, Zancai P, Bortolin MT, Mazzucato M, et al. High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma:pathogenic and clinical relevance. Infect Agents Cancer 2007;2:5.
157. Haznedaroglu IC, Benekli M, Ozcebe O, Savas MC, Gullu IH, Dundar SV, Kirazli S., Serum L-selectin and P-selectin levels in lymphomas. Haematologia 2000;30:27–30.
158. Mantur M, Kemona H, Kozlowski R, Kemona-Chetnik I., Effect of tumor stage and nephrectomy on CD62P expression and sP-selectin concentration in renal cancer. Neoplasma 2003;50:262–265.
159. Hottz ED, Oliveira MF, Nunes PC, Nogueira RM, Valls-de-Souza R, Da Poian AT, Weyrich AS, Zimmerman GA, Bozza PT., Bozza FA., Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. JTH 2013;11:951–962.
160. Lapinski TW, Pogorzelska J, Grzeszczuk A, Swiderska M, Kowalczuk O, Niklinski J, Flisiak R., The importance of sCD40 and sCD40L concentration in patients with chronic HCV infection and HIV co-infection. Przeglad Epidemiol 2014;68(11–5):105–108.
161. Davidson DC, Hirschman MP, Sun A, Singh MV, Kasischke K, Maggirwar SB., Excess soluble CD40L contributes to blood brain barrier permeability in vivo:implications for HIV-associated neurocognitive disorders. PloS One 2012;7:e51793.
162. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, De Angelis V, Pozzato G., Platelet production and destruction in liver cirrhosis. J Hepatol 2011;54:894–900.
163. Halim A, Kanayama N, el Maradny E, Nakashima A, Bhuiyan AB, Khatun S, Terao T. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia:their significances. Am J Obstetrics Gynecol 1996;174:272–277.
164. Trousseau, A., Phlegmasia alba dolens. Lectures on Clinical Medicine, Delivered at the Hotel-Dieu, Paris. Vol. 5 London, England:New Sydenham Society; 1865:281–332.
165. Lee AY, Levine MN. Venous thromboembolism and cancer:risks and outcomes. Circulation 2003 Jun 17;107(23 Suppl 1):I17–21.
166. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013 Sep 5;122(10):1712–23.
167. Lutgens E, Daemen MJ., CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27–32.
168. Chen W, Liang X, Syed AK, Jessup P, Church WR, Ware J, Josephson CD, Li R., Inhibiting GPIbα Shedding Preserves Post-Transfusion Recovery and Hemostatic Function of Platelets After Prolonged Storage. Arterioscler Thromb Vasc Biol. 2016Jul 14. pii:ATVBAHA.116.307639. [Epub ahead of print]
169. O’Halloran JA, Dunne E, Gurwith M, Lambert JS, Sheehan GJ, Feeney ER, Pozniak A, Reiss P, Kenny D, Mallon P., The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Med. 2015 Nov;16(10):608–19.